.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists have recently developed a groundbreaking cancer immunotherapy nanoplatform known as HA-PGMC. This platform addresses a significant challenge in oncology: the immunosuppressive tumor microenvironment. Specifically, cold tumors often resist standard treatments due to minimal T cell infiltration. By incorporating copper peroxide nanodots and glucose oxidase into a metal-organic framework, this system effectively redefines tumor treatment strategies.
The HA-PGMC platform operates through a sophisticated catalytic cascade. Once it enters the acidic and glucose-rich environment of a tumor, it releases iron and copper ions. These ions work together to produce abundant hydroxyl radicals. Furthermore, the copper ions deplete glutathione, which is a natural antioxidant that often protects cancer cells. Consequently, this dual action leads to significant oxidative stress, mitochondrial dysfunction, and lipid peroxidation within the tumor cells.
One of the most vital features of this cancer immunotherapy nanoplatform is its ability to trigger immunogenic cell death (ICD). It promotes the exposure of calreticulin and the release of HMGB1 from dying cancer cells. These signals effectively \"reprogram\" cold tumors into \"hot\" tumors. As a result, the immune system can recognize and attack the cancer more efficiently. This transformation creates a powerful synergy when combined with immune checkpoint blockade therapy.
Moreover, the HA-PGMC nanoplatform exhibits minimal toxicity to healthy cells. Researchers observed robust antitumor effects in laboratory settings, suggesting a high degree of specificity. Therefore, this technology represents a promising avenue for overcoming current limitations in clinical cancer immunotherapy. It simultaneously provides potent chemodynamic therapy while remodeling the immune landscape of the tumor.
A cold tumor is a type of cancerous growth that has very few immune cells, specifically T cells, around or inside it. This lack of immune activity makes the tumor resistant to conventional immunotherapies.
The platform induces immunogenic cell death by generating massive amounts of reactive oxygen species. This process releases signals that attract immune cells to the tumor, essentially making the \"cold\" environment \"hot\" and active.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always seek the advice of a qualified health provider regarding medical conditions. Refer to the latest local and national guidelines for clinical practice.
References
Lee ML et al. ROS Self-Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment. Adv Sci (Weinh). 2026 Apr 27. doi: 10.1002/advs.202523039. PMID: 42043835.
Wang S, et al. ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation. PMC. 2024;12(3):45-58.
Chen X, et al. Recent advances of cancer chemodynamic therapy based on Fenton chemistry. Chemical Science. 2022;13(4):1120-1135.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a ROS self-supplying nanoplatform (HA-PGMC) to enhance chemodynamic therapy and immunotherapy by reprogramming cold tumors....
4 months ago
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Left ventricular thrombus is a severe complication of acute decompensated heart failure. This clinical review explores the pathophysiology, imaging challenges, and pharmacotherapeutic considerations of laminated thrombi, evaluating the evolving role of direct oral anticoagulants versus traditional warfarin.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
